U.S. Healthtech Stock News

The Tate & Lyle takeover by US-based Ingredion has turned the spotlight onto consumer staples stocks that could sit on the path of the next merger or acquisition. A £2.7b price tag, a 60% premium to pre-deal speculation levels and plans for a combined $9.9b revenue base are a clear reminder that scale, cost cutting and product portfolios are firmly in focus. This article looks at 3 stocks that appear directly exposed to the same set of forces, helping you decide whether these M&A currents...

Arqit Quantum (NasdaqCM:ARQQ) has agreed to a US$7 million settlement resolving all U.S. securities class actions, closing multi year disputes over alleged misstatements about its quantum encryption technology and revenue sources. See our latest analysis for Arqit Quantum. The recent 7 day share price return of 79.3%, including a 7.9% move in the last session to US$24.38, suggests momentum has picked up quickly, even though the 1 year total shareholder return is still down 41.5% and the 5...

Coca-Cola FEMSA, S.A.B. de C.V. recently declared a quarterly dividend of US$0.9973 per share payable on July 24, 2026, while also confirming a board change with Sedef Salingan Sahin replacing Jennifer K. Mann as a Series D director earlier in June. These moves, alongside recent improvements in revenue and net profit, highlight how the bottler is coupling capital returns with governance continuity and operating strength. With this combination of a higher cash payout and steady operations,...

Recently, Rayonier Inc. reported a valuation score of 8.90, placing it 52nd out of 191 Residential & Commercial REITs, alongside a P/E ratio of 6.90, while institutional shareholdings rose as major investors such as Cohen & Steers Capital Management and BlackRock increased their positions and Mason Hawkins remained the largest holder despite slightly reducing its stake. This combination of a relatively low earnings multiple and rising institutional ownership suggests that professional...

In recent days, Envista Holdings Corp has seen growing institutional ownership, a high valuation multiple, and technical indicators pointing to positive price momentum, all within a relatively low-beta risk profile in the Healthcare Equipment & Supplies industry. An interesting angle is Envista’s combination of a very high institutional shareholding score with limited disclosed valuation metrics beyond its P/E ratio, leaving some aspects of market expectations less transparent. We’ll now...

In its latest quarterly update, Collegium Pharmaceutical reported year-over-year revenue growth of 8.87% and a very large increase in net profit, alongside strong financial scores for profitability, operational efficiency, and growth potential. These results suggest recent spending and operational adjustments are starting to translate into much stronger earnings power, easing earlier concerns about whether the company’s investments would improve profitability. Now we’ll examine how this...

With the Federal Reserve holding rates steady at 3.5% to 3.75% and signaling a steady, data focused approach under Chair Kevin Warsh, many investors are looking again at stable dividend paying blue chip stocks as potential anchors for their portfolios. Policy stability, ongoing geopolitical tension, and volatile oil prices are creating a mixed backdrop, but consistent dividends and stronger balance sheets can help smooth some of that noise. This article walks through three stocks from our...

In recent months, TFS Financial Corp has reported modest year-over-year improvements in quarterly revenue and net profit, even as some financial datapoints remain undisclosed and its operating efficiency score lags most peers in the Banking Services industry. At the same time, institutional ownership has climbed to the highest rank in its sector, with firms such as Dimensional Fund Advisors, BlackRock, State Street, and investor James Simons all increasing their stakes, signaling strong...

Why Zymeworks’ Cryo‑EM Breakthrough Matters for the Stock Zymeworks (ZYME) just reported a collaboration with Gandeeva Therapeutics that used high resolution cryo electron microscopy to map a small antigen bound to a Zymeworks antibody, sharpening insight into antibody epitope binding. For you as a shareholder or potential investor, the key point is that this work goes beyond a headline partnership announcement and delivers specific structural data, including a 2.6 Å view of nine amino acids...

Worthington Steel (WS) is back in focus after reporting quarterly revenue of US$769.80 million and net profit growth of 24.64% year over year, figures that sharply contrast with mixed technical signals. See our latest analysis for Worthington Steel. At a latest share price of US$40.73, Worthington Steel’s 1-day share price return of 3.90% contrasts with a 7-day decline of 6.26%. Its 1-year total shareholder return of 69.30% and 90-day share price return of 24.82% point to momentum that has...

Talks between Russia and China over the Power of Siberia 2 gas pipeline, combined with disruption risks around the Strait of Hormuz, are reshaping how investors think about global energy infrastructure. Changing trade routes, unresolved pricing and financing questions, and shifting export priorities can affect everything from earnings stability to access to capital for pipeline and midstream companies. This article walks through 3 stocks from our Global Energy Infrastructure and Natural Gas...

Conexeu Sciences (CNXU) has drawn fresh attention after expanding its board and executive team, including naming co founder David Bogart as Chief Commercial Officer, as it moves its CXU wound care platform toward FDA 510(k) preparation. See our latest analysis for Conexeu Sciences. Recent appointments around the CXU platform come after a period of mixed trading, with a 7 day share price return of 17.63% and a 30 day share price return that declined 7.78% from a latest close of $13.28. This...

The Federal Reserve’s signal that it may slow interest rate hikes, along with moderating inflation and softer Treasury yields, is reshaping how investors think about growth stocks. When borrowing costs and inflation pressures shift, expectations for future earnings and valuations can also change. Some companies with solid market value and healthier balance sheets may look better placed than others if financing conditions become less restrictive. This article walks through three growth focused...

Cooling core inflation at 3.3% and a softer 1.6% GDP print are giving investors a mixed signal, while headline inflation at 3.8% and higher gasoline prices keep pressure on the energy sector. With some traders now expecting the Fed to hold rates longer and even consider a hike in early 2025, pricing power, balance sheet strength, and exposure to consumer spending all matter more. This article discusses three U.S. energy sector stocks from our screener that appear particularly exposed to these...

Smith & Wesson Brands, Inc. has reported past fourth-quarter 2026 sales of US$178.39 million and net income of US$16.22 million, alongside full-year sales of US$523.85 million and net income of US$18.48 million, and announced a quarterly dividend of US$0.13 per share payable on July 15, 2026. The combination of higher year-over-year quarterly and annual earnings per share from continuing operations and the continued cash return via dividends highlights management’s focus on both...

In the past few days, Acushnet Holdings reported quarterly results showing revenue growth and a larger increase in net profit, alongside strong price momentum and supportive technical indicators. Despite slightly weaker institutional ownership and a relatively high earnings multiple, the company’s combination of improving earnings and top-ranked momentum appears to be reinforcing investor confidence in its underlying golf-focused business. Now we’ll explore how this combination of stronger...

Global trade is becoming more fragmented, with higher tariffs, protectionist policies and fresh risks to cross border digital commerce. That mix can create headwinds for companies built on long supply chains, while potentially giving an edge to businesses that earn most of their revenue closer to home. This article looks at how the latest World Trade Organization developments and geopolitical tensions might affect a group of stocks exposed to these shifts in trade, and highlights 3...

Global markets are being pulled in different directions by inflation headlines, shifting central bank signals, and energy and trade data, so it is no surprise that many investors are focusing on companies where analysts still see solid earnings growth potential and reasonably sound balance sheets. The Healthy high growth potential screener filters for exactly that, highlighting stocks that analysts expect to grow earnings over the next 3 years while meeting basic financial strength checks. In...

Franklin Electric recently reported past quarterly results showing revenue up 9.93% year-over-year and net profit up 10.91%, with a financial health score of 7.04 and average operating efficiency versus peers. At the same time, bullish technical indicators pointing to a buy signal and strong price momentum highlight how current trading trends are aligning with the company’s healthier fundamentals. Now we’ll examine how this combination of solid quarterly revenue and profit growth may...

Black Hills Corp. recently reported continued progress on its proposed 1.8‑gigawatt data center project in Cheyenne, Wyoming, including equipment procurement, over US$200,000,000 in refundable customer construction contributions, and regulatory filings to support new substation infrastructure. An interesting aspect is that the prospective large-load customer is directly funding long lead-time generation milestones and substation development, signaling strong commitment to this long-horizon...

Cellebrite DI (NasdaqGS:CLBT) is drawing fresh attention after announcing general availability of Cellebrite Genesis, an AI-driven digital evidence tool that early law enforcement users report is reshaping how complex investigations are handled. See our latest analysis for Cellebrite DI. The Cellebrite DI share price has pulled back in recent months, with a 90 day share price return of 10.09% and a year to date share price return of 28.08% in the red. However, the 3 year total shareholder...

If you are wondering whether Royal Gold at around US$214.82 really offers value today, the first step is understanding what the current share price is and is not telling you. The stock is up 3.5% over the last week, even though it is down 3.4% over the last 30 days and down 2.8% year to date, while the 1 year and 3 year returns of 20.8% and 95.0% put its recent performance in a very different light. Recent coverage has focused on how Royal Gold fits into the broader materials and mining...

CME Group (NasdaqGS:CME) has filed a lawsuit against the Commodity Futures Trading Commission over the regulator's approval of crypto perpetual futures. The case centers on how these perpetual futures are classified under Dodd-Frank and raises concerns about regulatory arbitrage and benchmark licensing. This dispute marks a rare public clash between CME Group and its primary U.S. derivatives regulator. CME Group, the operator of major futures and options exchanges, sits at the center of...

Fabrinet (NYSE:FN) is being included in a new lineup of leveraged single stock ETFs. The ETF provider has announced the addition as part of an expanding leveraged product range. This move is expected to affect trading patterns by increasing short term activity and speculation in Fabrinet shares. Fabrinet enters this ETF-related spotlight with a current share price of $573.76 and a value score of 3. The stock is up 19.7% year to date and has gained 115.5% over the past year. Returns over the...